Frontlight ResearchEarly access
CompletedPhase 2
Linezolid for Syphilis Pilot Study
Key facts
- Who runs it
- University of Southern California
- Where
- Chicago, Greensboro, Jackson, and Providence, United StatesSee the 5 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 24 people enrolled
- Started
- 28 Sept 2023
- Ended
- 30 Oct 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Group B, Linezolid 10d
- Group A, Penicillin
- Record updated
- 4 November 2026
Who can take part
- Age
- 16 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Diagnosed cases of primary, secondary or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment
- 16 years of age or older
- Able to provide informed consent/assent
- Individuals with HIV infection must be on treatment for HIV-infection and virologically suppressed (viral load < 200 copies/mL) or have a CD4 count ≥ 350 cells/mm3 as of their most recent test prior to enrollment
Who cannot take part
- Participants who receive certain psychotropic medications, e.g., MAO inhibitors, SNRIs, SSRIs
- Recent (within the past 7 days) or concomitant antimicrobial therapy with activity against syphilis, namely azithromycin, tetracycline, doxycycline, cefixime, ceftriaxone or other beta lactam antibiotics (e.g. amoxicillin)
- Individuals with known myelosuppressive conditions or receiving myelosuppressive medication
- Individuals with HIV infection who report HIV treatment interruption for more than 4 weeks since their most recent viral load or CD4 test
- Individuals with known end renal stage disease, for example individuals in hemodialysis
- Self-reported allergy to linezolid or penicillin
- Pregnancy or a positive pregnancy test on the day of enrollment
- Patients showing signs and symptoms of neurosyphilis
- Serofast RPR titer, defined as persistently positive RPR titer without more than 4-fold (2-titer level) change for 12 months or greater
- Individuals weighing 150kg (330 lbs) or more
- Unwilling or unable to attend follow-up visits
Where in United States
- Howard Brown HealthChicago, United States
- Wake Forest Baptist HealthGreensboro, United States
- Open Arms Healthcare CenterJackson, United States
- University of Mississippi Medical CenterJackson, United States
- Open Door HealthProvidence, United States
About the trial
What the trial wants to find out
The study aims to evaluate the efficacy of linezolid for the treatment of syphilis.
The 2 groups in the trial
- Linezolid 10 DayTreatment being tested
Oral linezolid 600mg, taken twice a day for 10 days
Treatment: Group B, Linezolid 10d
- Benzathine Penicillin GExisting treatment, for comparison
Single intramuscular injection of 2.4 million units of benzathine penicillin G
Treatment: Group A, Penicillin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pilot Study of Linezolid for Early Syphilis Treatment
- Record updated
- 4 November 2026